Public Therapeutic Company

Public Therapeutic Company	Finalist	Reasons to vote for this company
	Altimmune, Inc.	1. Recently acquired ALT-801, a differentiated and highly potent GLP-1/ glucagon dual agonist for the treatment of NASH. We plan to begin a Phase 1 trial during 2020. 2. Recently awarded $3.7 million to perform a Phase 1b clinical trial for our intranasal anthrax vaccine candidate, NasoShield. Data readouts will occur in the second half of 2020. This is a highly differentiated candidate that could disrupt the current anthrax vaccine market. 3. We are planning to file a US IND for our chronic hepatitis B immunotherapy, HepTcell, in 2020 with a North American trial to being soon thereafter.
	Arcturus Therapeutics	1. We are the cheapest and most attractively valued public company in the mRNA industry with leading players like Moderna (MRNA), Translate Bio (TBIO) and BioNTECH (BNTX). 2. We have a platform strategy with multiple strategic partners including Johnson & Johnson (JNJ), Takeda, Cystic Fibrosis Foundation, Ultragenyx (RARE), which may generate over $1 billion in milestone payments and royalties. 3. Our mRNA technology can potentially change the healthcare industry by creating life and curing or preventing diseases.
	BrainStorm Cell Therapeutics	1. BrainStorm has outstanding science and the NurOwn platform has tremendous potential for meeting critical unmet medical needs in neurodegenerative disease 2. BrainStorm is small, stealthy team, with 80 percent of the employees dedicated to science and moving medical discovery forward, while the management team is experienced in all phases of drug development and well positioned to execute the Company's overall business strategy 3. In addition to achieving top line data in the fully enrolled Phase 3 ALS clinical trial, Brainstorm is looking to complete enrollment of the phase 2 progressive MS clinical trial, and consider bringing to the clinic additional cell-based therapy indications so that we continue to lead the CNS regenerative medicine space, which we believe is the future of medicine.

	Eloxx Pharmaceuticals	1. Clinical stage biotech creating novel therapies to address one of most challenging mutation types across many rare diseases - nonsense mutations. 2. Advancing lead compound in US/EU Ph 2 program focused on the 12% of individuals living with Cystic Fibrosis that still have no disease-modifying therapy. 3. Achieved a statistically significant increase in a key measure in a Cystinosis Ph2 trial demonstrating biologic response in creating a previously missing vital protein.
	RespireRx Pharmaceuticals Inc.	1. Breakthrough compounds in areas with significant unmet needs including sleep apnea, ADHD and recovery from spinal cord injury. 2. Advanced clinical stage compounds in Phase 2. 3. Clinical data demonstrate target engagement and therapeutic effects.
	Salarius Pharmaceuticals	1. Salarius went public in July 2019 and began trading its common stock on the Nasdaq Commons Market. 2. Salarius is harnessing research into the epigenetic causes of cancer, to develop Seclidemstat, a potent, reversible LSD-1 inhibitor that is now in a Phase 1/2 clinical trial in Ewing sarcoma, a rare pediatric bone cancer with no targeted therapies. The drug is also being studied in advanced solid tumors and glioblastoma. 3. With Seclidemstat, Salarius expects to have a meaningful impact on Ewing sarcoma. It is believed to be the most advanced reversible LSD-1 inhibitor now in the clinic. Salarius expects to read out early cohort data in 2020.
	SCYNEXIS	1. According to the CDC, more than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result. SCYNEXIS is the leading antifungal company armed with the first molecule in an entirely new class of antifungals, in a time of increasingly common, multi-drug resistant fungal infections such as Candida auris and Vulvovaginal candidiasis (VVC). 2. Reported superior positive topline results from a Phase 3 study in VVC with a second Phase 3 study on track for top-line results in Q2 2020. SCYNEXIS is poised to be the first to market in VVC with a potential NDA submission in the second half of 2020.

		3. Candida auris was recognized as an an urgent threat by the CDC for the first time due to its multidrug resistance, uncanny ability to spread, and high mortality rate, and SCYNEXIS represents the most advanced clinical trial against C. auris today with Phase 3 data.
	Seelos Therapeutics	1. Seelos' focus is exclusively in indications of high unmet medical need and rare terminal diseases. 2. Seelos' SLS-002 is focused on the suicide crisis that exists globally to treat patients in acute crisis situations initially in the Emergency Room. 3. Seelos' SLS-005 will be first studied in Sanfilippo syndrome A&B patients but with the help of the Team Sanfilippo Foundation we are making it available in an Expanded Access program for all types; A,B,C, and D.
	Syndax Pharmaceuticals, Inc	1. A Phase 3 readout in the first half of 2020 for a first-in-class mechanism in hormone receptor positive Breast Cancer 2. A Phase 1/2 clinical POC readout in 2020 for a first-in-class, novel mechanism for the treatment of MLL-r leukemias. 3. A Phase 1/2 clinical POC readout in 2020 for a first-in-class, novel mechanism for the treatment of chronic graft-versus-host disease. And all within the next 12 months!

Private Therapeutic Company

Private Therapeutic Company	Finalist	Reasons to vote for this company
	Amplyx Pharmaceuticals	1. We are developing therapies that treat life-threatening diseases caused by life-saving therapies. Immunocompromised patients, such as cancer or transplant patients, are at risk of opportunistic diseases that can be more life-threatening than the original diagnosis. 2. We are developing novel, safe assets: Fosmanogepix, a new class of antifungal agent with activity against drug-resistant pathogens and MAU868, a monoclonal antibody against BK virus that causes devastating disease in transplant patients. 3. With decades of collective clinical development experience and passion, we have the right team to execute on our corporate goals to develop effective therapies in areas of high unmet need.
	Axial Biotherapeutics	1. Axial, a clinical stage biotech company approach to treating CNS diseases through the gut-brain axis is a radical departure from the belief that neurological disorders originate exclusively in the brain. 2. The company's two lead programs in Autism and Parkinson's represent significant unmet need with sizable market opportunities for a safe, gut-targeted treatment. 3. Axial's experienced management team has a proven track record of bringing drugs to market, i.e., Vortioxetine and Horizant from early development through regulatory approval and commercial launch. The Company is backed by a highly respected board, advisors, and investors, and has rapidly built a pipeline of novel small-molecules.
	AZTherapies, Inc.	1.AZTherapies is a leader in innovation, using a differentiated approach that recognizes neuroinflammation as the root cause of serious neurodegenerative diseases. 2.The company's lead candidate, ALZT-OP1, has the potential to halt or slow Alzheimer's disease early in its progression and to make a significant global impact for patients; the COGNITE Phase 3 clinical trial is now fully enrolled with data expected in late 2020, creating a unique, near-term investment opportunity. 3.Further harnessing the power of neuro-immunology, the company is also advancing clinical and pre-clinical programs targeting post-ischemic stroke cognitive impairment, ALS, and other indications.

	Cantex Pharmaceuticals	1. Successful randomized phase 2B study in acute myeloid leukemia, with improvement of event-free survival, relapse-free survival and overall survival. 2. Re-purposing disulfiram in combination with copper in a unique formulation for treatment of pancreatic cancer (in phase 2 now) and soon for triple-negative metastatic breast cancer. 3. Management with strong and consistent track record of developing major commercially successful products for cancer and for neurologic indications.
	Censa Pharmaceuticals	1. Censa's lead program (CNSA-001) demonstrated superiority to current 1st line therapy KuvanÂ® (sapropterin) in a head-to-head Phase 2 study in phenylketonuria (PKU) patients 2. Additional Phase 2 study results in 2020, including primary BH4 Deficiency, diabetic gastroparesis and Parkinson's Disease. 3. On track to initiate Phase 3 in 2H 2020 and have agreement with FDA on a single Phase 3 placebo-controlled pivotal study for approval in PKU with blood phenylalanine (Phe) reduction as the primary endpoint.
	EIP Pharma	1. Working on the leading mechanism for Alzheimer’s disease (AD). Prior experimental approaches have gone after specific aspects of AD pathogenesis (e.g. amyloid, inflammation, tau). EIPâ€™s oral drug, neflamapimod targets a protein within the synapse upon which all these other mechanisms converge. 2.A recently completed phase 2b six-month clinical study in early-stage AD demonstrated target engagement and proof-of-mechanism for neflamapimod through reducing CSF biomarkers related to the convergence point targeted by neflamapimod. 3.The development program is ready to enter phase 3 in AD. Phase 2 clinical trials in early-stage Huntington’s disease and dementia with Lewy bodies are ongoing.
	Kato Pharmaceuticals	1. Novel therapeutic 2. Unmet medical need 3. Massive market in Diabetic Retinopathy

	Passage Bio	1. Passage Bio is one of the few end-to-end gene medicine companies leveraging the deep AAV expertise of Dr. Jim Wilson, who is a co-founder of the company along with the rare disease drug development and commercialization expertise of cofounder and CEO Dr. Stephen Squinto. 2. Passage Bio is focused on developing life-transforming and life-saving genetic medicines for life-threatening rare monogenic CNS diseases. 3. Passage Bio has a very deep pipeline focusing initially on 6 indications with an option to license 6 more from the University of Pennsylvania.
	Rgenix, Inc.	1. We're uncovering miRNA biology and how it regulates gene expression beyond DNA, epigenetics and siRNA. 2. We develop drugs against novel targets in novel key cancer pathways. 3. We look at the tumor from an overarching system integrating diverse approaches such as tumor metabolism, innate immunity, angiogenesis and apoptosis.
	WindMIL Therapeutics	1. Unique cell therapy platform based on bone marrow-derived T cells, which are naturally antigen-specific and contain a high percentage of memory T cells. 2. Awaiting data from a Phase 2 high-risk multiple myeloma study and initiating a Phase 2 study in PD-1 relapsing/refractory NSCLC. 3. Bone marrow-derived T cells can also be used as the basis for CAR-T therapy, where their native TCR remains functional both after transduction and CAR engagement, addressing a key challenge of current CAR T therapies (antigen escape).

Diagnostics and Beyond

Diagnostics and Beyond	Finalist	Reasons to vote for this company
	AiCure	1. Building on our core technology measuring adherence in clinical trial populations, we are pursuing growth in multiple directions. We continue to broaden the range of therapeutic areas and indications explored, including oncology, inflammatory disease, and cardiovascular medicine. 2. We address more specific clinical trial scenarios, partnering with sponsors to develop approaches to both early- stage (e.g. PK, DDI studies) and late-stage (e.g. registrational) studies. 3. We continue to develop partnerships creating and validating novel digital biomarkers for a range of observable patient symptoms, such as tremor, fatigue, and changes in affect.
	Alveo Technologies, Inc.	1. Alveo has created a ground-breaking diagnostic platform combining molecular scale detection of nearly any pathogen with digital health capabilities facilitating infectious disease diagnosis, treatment and surveillance, for everyone, anytime, everywhere in the world. 2. The impact to public health is significant as our product is an over-the-counter molecular diagnostic tool that is low cost and convenient to use preventing epidemics and pandemics. 3. Alveo's platform will contribute to the revolution of how consumers and patients interact with health care providers enabling rapid intelligent intervention.
	Baebies	1. We save babies. By screening for rare, life threatening diseases in the first days of life we have saved 150 newborns so far! 2. Our diagnostic devices are easy to adopt, easy to use, and have no special requirements of the adopting site or staff. 3. Because our solutions are competitive, they enjoy adoption in the U.S. and translate to other, less resource-intense healthcare markets. We are Baebies with an extra "e" because everyone deserves a healthy start.
	BioSapien Inc.	1. BioSapien Inc. is an early-stage biotech company developing novel biodegradable implantable products that deliver active pharmaceutical ingredients (APIs) for oncology indications. 2. Our patented MedChip technology enables precise delivery of FDA approved drugs directly to cancerous cells, thereby reducing harmful side-effects and dramatically reducing costs associated with traditional

		systemic intravenous chemotherapy. 3. The MedChip technology has shown promising in-vitro data, and we are in the process of obtaining in-vitro release profiles and initiating in-vivo pilot studies
BRAVA Diagnostics	Brava Diagnostics	1. NextGen test for heart attack: Among the first point-of-care high-sensitivity troponin tests. 2. Lab-quality sensitivity and precision. 3. Guides rapid rule-out and safe discharge of low-risk chest pain patients.
BREAKTHROUGH GENOMICS	Breakthrough Genomics	1. With Groundbreaking AI, Breakthrough Genomics aims to achieve the impossible: transform the way that genomic data is interpreted so diseases can be predicted and targeted treatments can be discovered. 2. We are a game changer, removing the bottleneck problem with genomic data interpretation, and transforming clinical genomic testing to achieve full potential of precision medicine. 3. We have a great team with combined 60 years of experience in using AI to solve medical genetics problems.
ENDRA LIFE SCIENCES	ENDRA Life Sciences Inc.	1. ENDRA Life Sciences is looking at ultrasound in a whole new way. The company's Thermo-Acoustic Enhanced UltraSound (TAEUS) will revolutionize what clinicians can see and do at the point of care in ways previously possible only with CT or MRI. 2. TAEUS' first clinical application will enable a non-invasive and cost-effective method for detecting Non-alcoholic Fatty Liver Disease (NAFLD). Future TAEUS applications will address other unmet clinical needs, such as visualizing tissue temperature during energy-based surgery. 3. ENDRA anticipates approval of the TAEUS liver application in the EU and US by mid-2020 followed by commercial launch in both markets.
Genomic expression	Genomic Expression ApS	1. We can truly individualize cancer care utilizing our OneRNA data platform based on RNA sequencing. 2. RNA is coding for proteins and are now also a target for drugs directly and a drug itself. 3. We typically find a handful of already approved drugs in all the patients we analyze. That means we have the potential of extending life for most patients by refurbishing existing drugs on an individual patient basis

	Intact Genomics, Inc.	1. Most advanced and unique technologies. 2. Daunting potential and impact. 3. Totally revolutionize drug discovery, saving lives, and a moon-shot project.
	T-NeuroPharma	1.Our Alzheimer's diagnostics technology is based on the breakthrough discovery that an abnormal population of T-Cells entering the brain is one of the earliest causative events in Alzheimer's pathology. 2.These pathologic T-Cells can be detected in a blood sample very early in the progression of the disease. This simple blood test is more a more effective diagnostic than costly MRI imaging, and invasive Cerebral-Spinal Fluid sampling. 3.The T-cells can also be blocked from entering the brain, preventing progression of AD. Ideally, the biomarker will be utilized to detect the disease early, then the treatment will be administered to prevent the disease from ever progressing.